|
| |
Merck & Co., Inc.
| Dirección del domicilio social: P.O. Box 100, One Merck Drive Whitehouse Station, NJ 08889 |  | Tel. 908-423-1000 Ofertas de empleo, inversores: www.merck.com Bolsa:  |
|
|
nombre  foto productos compara los precios |
Compremos local, ética y al mejor precio sobre Ethishop ! |
|
|
EVALUACIÓN « ÉTICA » DE MERCK
, grupo
y filiales
[haga clic sobre las imágenes abajo o sobre ayudo para más información] |
| Empleo: 16% de empleos suprimidos desde 1998 |
| Medio ambiente: 1 polucion(es) mayor(es) |
| Delincuencia financiera: 3 acto(s) de delincuencia financiera |
| Paraísos financieros: tiene actividad en 11 paraísos financieros |
| Ventas: más de 22 mil milliones de dolares/euros de ventas anual |
| Resultado: más de 45 mil milliones de dolares/euros de benefícios cumulados desde 1998 |
| Dirección: gana 186 veces el salario mediano de los EEUU (32000 $/año) |
| Influencia: 9 acto(s) de corrupción directa o lobbying |
| Publicidad & marketing: 5 práctica(s) dudosa(s) |
|
|
Pertinencia: actividad & quota de mercado |
año | actividad fuente |
| 2006 | Merck vende un 10% de las vacunas compradas en el mundo. | Les Echos  |
| 2006 | Merck es el septimo grupo farmacéutico mundial. | Les Echos |
|
Establecimientos mundiales y producción |
| año nombre | foto posición; remuneración fuente |
| 2002Lewent, Judy |  Director financiero; salario: 1.2 milliones US$; stock-options: 4.74 milliones US$; |
|
| año | práctica dudosa : imagen fuente |
| 2007 | Falsa publicidad: Merck va a pagar 58 millones de dólares para regular a l' amistoso una denuncia de treinta Estados americanos que l' acusaban d' haber recurrido a publicidad engañosa para elogiar los méritos de su antiinflamatorio Vioxx., retirado del mercado desde debido a sus peligrosos efectos secundarios.: | Les Echos |
| 2007 | Desinformación: Una comparación de los datos internos de Merck en 2001 con los resultados de dos pruebas clínicas hechas públicas en 2004 y 2005 revela "que la presentación de Merck en cuanto al riesgo de muerte vinculado al Vioxx en enfermos que sufren de Alzheimer podría haber sido minimizado intencionalmente", según un artículo del "Diario of the American Medical Asociación". Merck había retirado voluntariamente el Vioxx del mercado en septiembre de 2004 tras un estudio que ponía de manifiesto que el medicamento duplicaba el riesgo de accidentes cardiovasculares después de dieciocho meses de utilización diaria. El documento interno se obtuvo en los cuadros de los pleitos a los cuales Merck se enfrenta con respecto al Vioxx.: | Les Echos |
| 2007 | Desinformación: In June 2005, U.S. National Public Radio's Snigdha Prakash reported, "New documents obtained by NPR suggest that even as Merck was making Vioxx into a bestseller, the company was putting pressure on independent doctors. The company's apparent aim: to keep them from discussing evidence of Vioxx's potential safety problems. The documents show that Merck exerted pressure not only on individual doctors, but also on several of the nation's top medical schools." NPR described Merck's campaign to recruit the physician Gurkirpal Singh of Stanford University as a Vioxx spokesperson. "Merck wanted Singh on board because he was a senior researcher on a seminal study of arthritis patients," reported Prakash. Starting in 1998, Merck cultivated Singh; the physician soon became a Vioxx booster, being paid $2,500 per speaking engagement by Merck. But in 2000, a study suggesting heart problems among Vioxx users worried Dr. Singh. He asked Merck for the data. "I wanted to know how many heart attacks, how many strokes, how many deaths were occurring in each one of the groups, and what were these actual number of patients at risk, and how many ended up having an event," he told NPR. Merck originally promised to share the information with Singh, but never did. Singh began including his concerns in his public presentations on Vioxx. Merck began closely tracking Dr. Singh's activities. According to NPR: Almost a dozen Merck executives were involved [in tracking Dr. Singh]. A senior regional executive who had supervised Singh's scientific handlers sent this Oct. 4, 2000, e-mail: "I have in excess of 80 e-mails pertaining to interactions with Dr. Singh from March 1999 to present. The following is my best recollection of what has happened. Because of the sensitive nature of the following, I strongly encourage you not to share with anyone unless they clearly have a need to know." As Singh's public criticisms of Vioxx continued ("He was now promoting Vioxx's rival, Celebrex," and "being paid by Pfizer," reported NPR. Merck decided to start calling his superiors at Stanford. Stanford medical professor James Fries told NPR, "I received a call from a medical director at Merck, stating that someone on my staff had been making wild and irresponsible public statements about the cardiovascular side effects of Vioxx." Fries said the Merck representative "hinted there would be repercussions for Fries and Stanford if Singh's statements didn't stop. He was left with the sense that Merck's financial support to Stanford was at risk." traducir : | Sourcewatc. |
| 2005 | Desinformación: In June 2005, the ad agency Ogilvy & Mather Worldwide launched the first promotional campaign ever for Merck - a $20 million, 6-month campaign with the slogan "Merck. Where patients come first." The campaign was planned before the company was forced to withdraw its popular painkiller Vioxx, and before evidence came to light that Merck not only ignored evidence that Vioxx caused heart complications, but also heavily marketed the drug. The major goal of the Merck promotional campaign was "to build emotional ties between Merck and consumers": One television commercial shows cute children reacting in charming confusion to requests to define "measles," "mumps" and "chicken pox." "Most kids today don't have a clue about diseases adults remember, thanks to Merck's scientists," a female announcer says, adding: "We've invested billions to research heart disease and asthma. Now we're trying to make Alzheimer's, diabetes and cancer history too." … Also, more than 40 percent of the ads in the campaign are being devoted to information about what Merck calls its access programs, which are efforts to provide some consumers with prescription drugs either free or at reduced prices. traducir : valor: Merck. Where patients come first.; | Sourcewatc. |
| 2005 | Desinformación: Merck allegedly tried to censor vioxx critics. Merck hired Stanford University's Dr. Gurkirpal Singh in 1998 and paid him up to $2,500 for each talk he gave to other physicians about Vioxx. But when Singh became concerned about a 2000 study suggesting Vioxx increased the risk of heart attacks, Merck tracked Singh's public comments on Vioxx, eventually contacting his bosses at Stanford and hinting "there would be repercussions ... if Singh's statements didn't stop." Merck provides significant research funding to Stanford, a common arrangement between drug companies and universities. traducir : | NPR |
| 2005 | |  |
| 2005 | eslogan: Merck. Where patients come
first.; | |
| 2004 | "APCO Worldwide is supporting Merck's PR efforts for the controversial" -- and deadly -- "arthritis drug Vioxx, which was found to increase heart attack risk in patients," reports O'Dwyer's. traducir : | Sourcewatc. |
|
|
| año | empleados <> | impacto social : país fuente |
| 2008 | -1200 | Reestructuración interna: Merck elimina 1200 nuevos puestos de trabajo en los EE.UU., una semana después del rechazo por parte de la Food and Drug Administration de Cordaptive, su fármaco experimental contra el colesterol Cordaptive.: Estados Unidos | AP |
| 2005 | -7000 | Cierre/Quiebra: Merck will close 5 manufacturing plants, one research site and two preclinical development sites to trim costs by as much as $4 billion through 2010. About half of the job cuts will be in the U.S., Merck said. traducir : Estados Unidos | Bloomberg |
| 2003 | 62000 | | |
| 2002 | 78100 | | |
| 2001 | 69300 | | |
| 1999 | 62300 | | |
| 1998 | 57300 | | |
|
Impacto sobre el medio ambiente |
| año | delincuencia financiera | ventas | resultado | | recompra | fuente |
| 2006 |
Merck paga 2,3 mil millones dólares de impuestos, intereses y penalidades de impuestos para regular de mutuo acuerdo una investigación de la administración fiscal de los Estados-Unidos referentes al registro de sus patentes desde 1993 en países a escasa fiscalidad con el fin de pagar menos impuesto. |
| | | | | | Les Echos |
| 2005 |
Sued by the State of California for defrauding the state's $34 billion Medi-Cal program by inflating prices. "We're going to drag these drug companies into courts of law because they've been gouging the public," California Attorney General Bill Lockyer said at a news conference. For example, Medi-Cal paid $804.70 US for a bottle of the hypertension drug Atenolol. Providers such as doctors, clinics and pharmacists paid $33.85 US. As a result, providers reimbursed by Medi-Cal for Atenolol pocketed $770.85 US. The windfalls gave doctors, pharmacies and other providers an incentive to prescribe such drugs, which resulted in even more sales by drug makers, Lockyer said. traducir |
| | | | | | Canadian P. |
| 2003 |
| 22.49 | 6.83 | | | mil milliones US$ | |
| 2002 |
| 51.79 | 7.15 | | | mil milliones US$ | |
| 2001 |
| 47.72 | 7.28 | | | mil milliones US$ | |
| 1999 |
| 32.71 | 5.89 | | | mil milliones US$ | |
| 1998 |
| 26.9 | 5.25 | | | mil milliones US$ | |
|
|
|
|
Anuncia también un documental, un libro o un artículo o comenta el perfil de esta empresa.
Objetivo: presentar las actividades de la empresa, mejorar la exactitud de la evaluación ética, desarrollar una red de vigilancia.